Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

a technology of epithelial growth factor and antiher2 is applied in the field of combined therapy with antiher2 and antiher2 antibodies, which can solve the problems of poor prognosis and survival, her2 over-expression, etc., and achieve the effects of reducing metastasis, reducing metastasis, and reducing metastasis

Inactive Publication Date: 2007-09-27
F HOFFMANN LA ROCHE & CO AG
View PDF4 Cites 81 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The invention is about using a combination of an anti-VEGF antibody and an anti-HER2 antibody to treat breast cancer in patients who have failed previous therapy with an anti-VEGF antibody. This combination can increase the duration of survival, progression-free survival, response rate, and duration of response in patients with breast cancer. The invention also includes a method of reducing metastasis in patients with breast cancer who have failed previous therapy with an anti-VEGF antibody. The pharmaceutical composition includes an anti-VEGF antibody and an anti-HER2 antibody, which can be administered to patients who have failed previous therapy with an anti-VEGF antibody.

Problems solved by technology

HER2 is over-expressed in tumor cells and is correlated with poor prognosis and survival.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0024]Al references cited herein are hereby incorporated by reference in their entirety.

Definitions

[0025]The term “VEGF” according to the invention refers to the vascular endothelial cell growth factor (Swiss-Prot No. P 15692), alternative splicing forms (see e.g. Leung, D. W., et al., Science, 246 (1989) 1306-1309; and Houck, K. A., et al., Mol. Endocrin. 5 (1991) 1806-1814) and active fragments, preferably N-terminal fragments thereof.

[0026]The term “anti-VEGF antibody” according to the invention is an antibody that binds specifically to VEGF. The preferred humanized anti-VEGF antibody or variant anti-VEGF antibody herein binds human VEGF with a Kd value of no more than about 1×10−8M and preferably no more than about 5×10−9M. Preferably the anti-VEGF antibody is a monoclonal antibody that binds to the same epitope as recombinant humanized anti-VEGF monoclonal antibody generated according to Presta, L. G., et al., Cancer Res. 57 (1997) 4593-4599. A preferred antibody is bevacizumab...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular massaaaaaaaaaa
pHaaaaaaaaaa
weightaaaaaaaaaa
Login to View More

Abstract

The present invention provides a method of treating a breast cancer disease in a patient who has failed prior treatment with an anti-VEGF antibody, comprising administering to the patient a therapeutically effective amount of an anti-HER2 antibody while continuing said anti-VEGF antibody therapy. The invention also provides corresponding pharmaceutical kits and pharmaceutical compositions.

Description

PRIORITY TO RELATED APPLICATIONS[0001]This application claims the benefit of European Application No. EP06111523.4, filed Mar. 22, 2006 and EP06021815.3, filed Oct. 18, 2006, which is hereby incorporated by reference in its entirety.FIELD OF THE INVENTION[0002]The present invention is directed to combined therapy with anti-HER2 and anti-VEGF antibodies. In particular, the invention concerns the use of such antibodies to treat breast cancer disease in a patient who has failed prior breast cancer treatment with an anti-VEGF antibody.BACKGROUND OF THE INVENTION[0003]Angiogenesis is implicated in the pathogenesis of a variety of disorders which include solid tumors, intraocular neovascular syndromes such as proliferative retinopathies or age-related macular degeneration (AMD), rheumatoid arthritis, and psoriasis (Folkman, J., et al., J. Biol. Chem. 267 (1992) 10931-10934; Klagsbrun, M., et al., Annu. Rev. Physiol. 53 (1991) 217-239; and Garner, A, Vascular diseases, In: Pathobiology of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/395
CPCA61K2039/507C07K16/32C07K16/3015C07K16/22A61P35/00A61P35/02A61P35/04A61K39/395C07K16/00A61K39/3955A61K39/39558C07K2317/24
Inventor FRIESS, THOMASHASMANN, MAXSCHEUER, WERNER
Owner F HOFFMANN LA ROCHE & CO AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com